Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
This study is currently recruiting participants.
Verified March 2013
by Fred Hutchinson Cancer Research Center
Study NCT01434472 Information provided by Fred Hutchinson Cancer Research Center
First Received on July 26, 2011. Last Updated on March 27, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Recurrent Adult Burkitt Lymphoma
Additional conditions recognized in this trial
Burkitt Lymphoma
Lymphoma
Lymphoma, B-Cell
Lymphoma, Extranodal NK-T-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Lymphomatoid Granulomatosis
Lymphoproliferative Disorders
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
DNA Virus Infections
Epstein-Barr Virus Infections
Herpesviridae Infections
Immune System Diseases
Immunoproliferative Disorders
Leukemia
Leukemia, Lymphoid
Lymphatic Diseases
Lymphoma, T-Cell
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Experimental
Precancerous Conditions
Tumor Virus Infections
Virus Diseases
Interventions listed in this trial
fludarabine phosphate
total-body irradiation
yttrium Y 90 ibritumomab tiuxetan
cyclosporine
mycophenolate mofetil
rituximab
indium In 111 ibritumomab tiuxetan
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Cyclosporins
Fludarabine
Fludarabine monophosphate
Mycophenolic Acid
Vidarabine
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Antiviral Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
National Cancer Institute (NCI)
Back to top of Main Content
